Physician profile
Devi Sampat
NPI 1104212778
$13,006.83
in general payments reported to CMS, 2019-2025
68 companies · $3,089 in 2025
The $3,089 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.46 · 2020: $99.65 · 2021: $1,178 · 2022: $2,670 · 2023: $2,785 · 2024: $3,093 · 2025: $3,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,906 · Education: $61.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,906.26 |
| Education | $61.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $845.86 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $793.90 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $664.07 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $612.60 | 2021-2025 | Tagrisso, Lynparza, Enhertu |
| Daiichi Sankyo INC. | $591.90 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $571.39 | 2022-2025 | Talvey, Erleada, Tecvayli |
| Incyte Corporation | $567.69 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Eisai INC. | $545.66 | 2020-2025 | |
| Glaxosmithkline, LLC. | $501.49 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $463.34 | 2021-2023 | Padcev, Adcetris, Tukysa |
| Celgene Corporation | $460.02 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Abbvie INC. | $453.15 | 2022-2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $392.39 | 2021-2025 | |
| Genzyme Corporation | $384.34 | 2021-2025 | |
| Genentech USA, INC. | $334.62 | 2021-2025 | Venclexta, Alecensa, Tecentriq |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $297.94 | 2021-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $259.87 | 2021-2025 | Iclusig, Ninlaro, Fruzaqla |
| Exelixis INC. | $240.79 | 2022-2025 | Cabometyx |
| Gilead Sciences, INC. | $234.54 | 2023-2025 | Trodelvy |
| Amgen INC. | $207.56 | 2021-2023 | Lumakras |
| Jazz Pharmaceuticals INC. | $201.03 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $192.57 | 2021-2023 | Imbruvica |
| Stemline Therapeutics INC. | $192.32 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $188.07 | 2022-2025 | |
| Tersera Therapeutics LLC | $167.83 | 2021-2024 | Zoladex, Xermelo |
| Regeneron Healthcare Solutions, INC. | $162.77 | 2021-2024 | Libtayo |
| Lilly USA, LLC | $161.86 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Beigene USA, INC. | $161.00 | 2021-2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $149.20 | 2022-2025 | Ultomiris |
| Coherus Oncology, INC. | $143.21 | 2021-2025 | Loqtorzi |
| Emd Serono, INC. | $131.52 | 2022-2025 | Bavencio |
| Astellas Pharma US INC | $122.01 | 2022-2024 | Padcev, Xtandi, Xospata |
| Deciphera Pharmaceuticals INC. | $119.48 | 2021-2025 | Qinlock, Romvimza |
| Rigel Pharmaceuticals, INC. | $108.15 | 2021-2024 | Tavalisse, Rezlidhia |
| Beone Medicines USA, INC. | $106.64 | 2025 | Brukinsa, Tevimbra |
| Servier Pharmaceuticals LLC | $98.27 | 2022-2024 | |
| Taiho Oncology, INC. | $89.15 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $85.88 | 2021-2025 | Xpovio |
| Morphosys, US INC. | $79.40 | 2021-2024 | Monjuvi |
| Array Biopharma INC | $74.04 | 2022-2025 | Braftovi, Tukysa, Mektovi |
| Epizyme, INC. | $69.16 | 2021-2022 | |
| Sobi, INC | $62.54 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $48.19 | 2024 | Orgovyx |
| Foundation Medicine, INC. | $47.73 | 2022-2023 | Foundationone Cdx |
| Aveo Pharmaceuticals, INC. | $46.60 | 2022-2025 | |
| Tempus Ai, INC | $43.98 | 2024-2025 | Xt Cdx |
| Organon LLC | $41.98 | 2022-2023 | Ontruzant |
| Dova Pharmaceuticals | $40.39 | 2021 | |
| Myovant Sciences INC. | $38.93 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $34.64 | 2025 | |
| Tolmar, INC. | $32.33 | 2024 | |
| Acrotech Biopharma INC. | $31.93 | 2022-2025 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.14 | 2023 | Gilotrif |
| Pharmaessentia USA Corporation | $25.31 | 2025 | Besremi |
| Immunogen, INC. | $24.28 | 2023 | Elahere |
| Fennec Pharmaceuticals, INC. | $23.27 | 2025 | Fyarro |
| Mirati Therapeutics, INC. | $22.82 | 2024 | Krazati |
| Syndax Pharmaceuticals, INC. | $20.36 | 2025 | |
| Kyowa Kirin, INC. | $20.21 | 2024 | Poteligeo |
| Amneal Pharmaceuticals LLC | $19.55 | 2023 | Avastin |
| Cti Biopharma Corp. | $18.42 | 2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $17.45 | 2025 | Erleada |
| Recordati_rare_diseases_inc. | $17.28 | 2023 | Sylvant |
| Adc Therapeutics America, INC. | $16.90 | 2025 | |
| Geron Corporation | $15.91 | 2025 | Rytelo |
| Kite Pharma, INC. | $14.90 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.48 | 2023 | Truxima |
| Adaptive Biotechnologies Corporation | $13.63 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devi Sampat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.